The estimated Net Worth of Mark Jeffrey De Long is at least $3.15 million dollars as of 12 August 2024. Mark Long owns over 5,201 units of Apellis Pharmaceuticals Inc stock worth over $2,316,752 and over the last 3 years Mark sold APLS stock worth over $833,006.
Mark has made over 19 trades of the Apellis Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Mark exercised 5,201 units of APLS stock worth $72,034 on 12 August 2024.
The largest trade Mark's ever made was exercising 10,000 units of Apellis Pharmaceuticals Inc stock on 4 August 2022 worth over $155,200. On average, Mark trades about 2,732 units every 41 days since 2021. As of 12 August 2024 Mark still owns at least 60,395 units of Apellis Pharmaceuticals Inc stock.
You can see the complete history of Mark Long stock trades at the bottom of the page.
Mark's mailing address filed with the SEC is C/O APELLIS PHARMACEUTICALS, INC., 100 FIFTH AVENUE, 3RD FLOOR, WALTHAM, MA, 02451.
Over the last 6 years, insiders at Apellis Pharmaceuticals Inc have traded over $44,114,337 worth of Apellis Pharmaceuticals Inc stock and bought 1,248,415 units worth $38,006,599 . The most active insiders traders include Venture Investments Ltd Mor..., Cedric Francois et Pascal Deschatelets. On average, Apellis Pharmaceuticals Inc executives and independent directors trade stock every 6 days with the average trade being worth of $665,393. The most recent stock trade was executed by James George Chopas on 3 September 2024, trading 550 units of APLS stock currently worth $21,720.
apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Apellis Pharmaceuticals Inc executives and other stock owners filed with the SEC include: